Vireo Growth (VREOF) Income from Continuing Operations (2020 - 2026)
Vireo Growth (VREOF) posted Income from Continuing Operations of 22500000.0 for Q1 2026, up 33.39% sequentially from 33778228.0 in Q4 2025, and down 246.15% YoY from 15394736.84 in Q1 2025.
Vireo Growth (VREOF) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Vireo Growth has reported Income from Continuing Operations for 7 years, with the latest figure at 22500000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 246.15% year-over-year to 22500000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 97511118.0 (down 250.81% YoY) and the FY2025 annual result came in at 81519908.0, down 191.06% from the prior year.
- Income from Continuing Operations advanced to 22500000.0 in Q1 2026 per VREOF's latest filing, from 33778228.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 668411.0 in Q2 2024 and troughed at 33778228.0 in Q4 2025.
- A 5-year average of 11678127.12 and a median of 8468970.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations jumped 90.95% in 2024, then tumbled 2134.26% in 2025.
- Over 5 years, Income from Continuing Operations stood at 9290798.0 in 2022, then soared by 75.54% to 2272837.0 in 2023, then tumbled by 590.82% to 15701281.0 in 2024, then sank by 115.13% to 33778228.0 in 2025, then soared by 33.39% to 22500000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 22500000.0, 33778228.0, and 26298861.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Vireo Growth | 492.80 Mn | 350.50 Mn | 95.30 Mn | -5.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.50 Mn |
| Dec 31, 2025 | -33.78 Mn |
| Sep 30, 2025 | -26.30 Mn |
| Jun 30, 2025 | -14.93 Mn |
| Mar 31, 2025 | -6.50 Mn |
| Dec 31, 2024 | -15.70 Mn |
| Sep 30, 2024 | -4.93 Mn |
| Jun 30, 2024 | -668,411.00 |
| Mar 31, 2024 | -6.71 Mn |
| Dec 31, 2023 | -2.27 Mn |
| Sep 30, 2023 | -5.73 Mn |
| Jun 30, 2023 | -7.39 Mn |
| Mar 31, 2023 | -8.47 Mn |
| Dec 31, 2022 | -9.29 Mn |
| Sep 30, 2022 | -9.57 Mn |
| Jun 30, 2022 | -6.10 Mn |
| Mar 31, 2022 | -17.68 Mn |
| Dec 31, 2021 | -14.09 Mn |
| Sep 30, 2021 | -6.84 Mn |
| Jun 30, 2021 | -6.99 Mn |